ES2999335T1 - Conjugates comprising a phosphorus (v) and a drug moiety - Google Patents

Conjugates comprising a phosphorus (v) and a drug moiety Download PDF

Info

Publication number
ES2999335T1
ES2999335T1 ES22817174T ES22817174T ES2999335T1 ES 2999335 T1 ES2999335 T1 ES 2999335T1 ES 22817174 T ES22817174 T ES 22817174T ES 22817174 T ES22817174 T ES 22817174T ES 2999335 T1 ES2999335 T1 ES 2999335T1
Authority
ES
Spain
Prior art keywords
optionally substituted
alkyl
conjugate
residue
substituted aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES22817174T
Other languages
English (en)
Spanish (es)
Inventor
Christian Hackenberger
Philipp Ochtrop
Jahaziel Jahzerah
Paul Machui
Dominik Schumacher
Jonas Helma-Smets
Isabelle Mai
Marc-André Kasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forschungsverbund Berlin FVB eV
Tubulis GmbH
Original Assignee
Forschungsverbund Berlin FVB eV
Tubulis GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forschungsverbund Berlin FVB eV, Tubulis GmbH filed Critical Forschungsverbund Berlin FVB eV
Publication of ES2999335T1 publication Critical patent/ES2999335T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/44—Amides thereof
    • C07F9/4461—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4476—Amides thereof the amide moiety containing a substituent or a structure which is considered as characteristic of aromatic amines (N-C aromatic linkage)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES22817174T 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety Pending ES2999335T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21207195 2021-11-09
PCT/EP2022/081345 WO2023083900A1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Publications (1)

Publication Number Publication Date
ES2999335T1 true ES2999335T1 (en) 2025-02-25

Family

ID=78592631

Family Applications (1)

Application Number Title Priority Date Filing Date
ES22817174T Pending ES2999335T1 (en) 2021-11-09 2022-11-09 Conjugates comprising a phosphorus (v) and a drug moiety

Country Status (15)

Country Link
US (2) US20230330258A1 (enExample)
EP (1) EP4429708A1 (enExample)
JP (1) JP2024540691A (enExample)
KR (1) KR20240100413A (enExample)
CN (1) CN118302197A (enExample)
AU (1) AU2022385379A1 (enExample)
CA (1) CA3237371A1 (enExample)
CL (1) CL2024001372A1 (enExample)
CO (1) CO2024005877A2 (enExample)
DE (1) DE22817174T1 (enExample)
ES (1) ES2999335T1 (enExample)
IL (1) IL312675A (enExample)
MX (1) MX2024005546A (enExample)
PE (1) PE20242107A1 (enExample)
WO (1) WO2023083900A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4637832A1 (en) * 2022-12-22 2025-10-29 Tubulis GmbH Conjugates comprising a phosphorus(v) moiety and a drug
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
AU2024332412A1 (en) 2023-09-01 2026-03-12 Tubulis Gmbh Methods of preparing phosphonamidate compounds
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof
US12521446B2 (en) 2024-02-27 2026-01-13 Bristol-Myers Squibb Company Anti-CEACAM5 antibody drug conjugates
WO2025262641A1 (en) 2024-06-19 2025-12-26 Pheon Therapeutics Ltd Antibody drug conjugates that bind cdcp1 and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US633410A (en) 1898-09-22 1899-09-19 George A Ames Ice-cutter.
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
JP2763020B2 (ja) 1995-04-27 1998-06-11 日本電気株式会社 半導体パッケージ及び半導体装置
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
EP0964702B1 (en) 1996-08-02 2006-10-04 Ortho-McNeil Pharmaceutical, Inc. Polypeptides having a single covalently bound n-terminal water-soluble polymer
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
NZ610239A (en) 2008-04-30 2014-11-28 Immunogen Inc Cross-linkers and their uses
NZ758049A (en) 2013-10-15 2024-03-22 Seagen Inc Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
AU2017320913B2 (en) 2016-09-01 2024-08-15 Forschungsverbund Berlin E.V. Chemoselective thiol-conjugation with alkene or alkyne-phosphonamidates
KR102772724B1 (ko) 2018-03-07 2025-02-24 포슝스베르분드 베를린 에.베. 알켄 또는 알킨-포스포노티올레이트 및 -포스포네이트로의 화학선택적 티올-접합
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物

Also Published As

Publication number Publication date
WO2023083900A1 (en) 2023-05-19
US20230330258A1 (en) 2023-10-19
CL2024001372A1 (es) 2024-10-25
KR20240100413A (ko) 2024-07-01
IL312675A (en) 2024-07-01
DE22817174T1 (de) 2024-12-12
CN118302197A (zh) 2024-07-05
CA3237371A1 (en) 2023-05-19
JP2024540691A (ja) 2024-10-31
US20250281634A1 (en) 2025-09-11
MX2024005546A (es) 2024-07-10
EP4429708A1 (en) 2024-09-18
CO2024005877A2 (es) 2024-07-08
PE20242107A1 (es) 2024-10-28
AU2022385379A1 (en) 2024-06-20

Similar Documents

Publication Publication Date Title
ES2999335T1 (en) Conjugates comprising a phosphorus (v) and a drug moiety
JP7556086B2 (ja) エリブリンをベースとする抗体－薬物コンジュゲート及び使用方法
US20240173427A1 (en) Glypican 3 antibodies and conjugates thereof
ES2987508T3 (es) Conjugados de anticuerpos y fármacos
JP2024540691A5 (enExample)
ES3001145T1 (es) Conjugados que comprenden un fosforo (v) y un resto de camptotecina
JP6208864B2 (ja) 安定性が改善された抗体−薬物結合体およびこれの用途
KR20060080535A (ko) 약물 콘쥬게이트 조성물
IL290698B2 (en) History of methanosinoids with peptide linkers and their conjugates
JP2022530524A5 (enExample)
JP2014516508A (ja) 抗体−薬剤コンジュゲート
AU2015340370B2 (en) Materials and methods relating to linkers for use in protein drug conjugates
BR112021010364A2 (pt) Composições farmacêuticas que compreendem conjugados de anticorpo-fármaco anti-191p4d12 e métodos de uso das mesmas
IL273384B2 (en) Methods of preventing methionine oxidation in immunoconjugates
WO2022001710A1 (zh) 用于抗体与药物偶联体(adc)制备的中间体及其制备方法和应用
CN101277716A (zh) 治疗癌症的抗体
WO2024235135A1 (zh) 大环化合物及其制备方法和用途
WO2024235131A1 (zh) 大环类药物偶联物及其制备方法和用途
RU2021130453A (ru) Бипаратопные fr-альфа антитела и иммуноконъюгаты
CN120923577A (zh) 大环类药物偶联物及其制备方法和用途
IL320287A (en) Novel anti-tpbg antibody and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof
RU2021104563A (ru) Конъюгаты антитело-лекарственное средство и их применение
HK1092730A (en) Drug conjugate composition
KR20140013417A (ko) 개선된 항암활성을 가지는 다특이성 항체-싸이토톡신 결합체 및 이를 포함하는 암 예방용 또는 치료용 조성물
NZ728857B2 (en) Materials and methods relating to linkers for use in protein drug conjugates